Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biejia Ruanmai Decoction (BJRM) is a Traditional Chinese Medicine (TCM) herbal formula developed and investigated by researchers at Fudan University, specifically within the Department of Neurology at Huashan Hospital. The decoction is primarily indicated for the treatment of cerebral small vessel disease (CSVD), a condition characterized by damage to the small arteries, arterioles, capillaries, and small veins in the brain. Based on TCM principles of "softening hardness and dissipating clumps" and "promoting blood circulation to remove stasis," the formula typically includes ingredients such as *Carapax Trionycis* (turtle shell), *Radix Salviae Miltiorrhizae* (Danshen), *Radix Astragali* (Huangqi), and *Hirudo* (Shuizhi). Clinical research suggests that BJRM may improve cognitive function, reduce the progression of white matter hyperintensities, and enhance microvascular integrity by modulating endothelial function and reducing neuroinflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biejia Ruanmai Decoction.